Serial extracellular volume quantification using cardiac magnetic resonance imaging in transthyretin amyloidosis patients treated with tafamidis - Takeaways - MDSpire

Serial extracellular volume quantification using cardiac magnetic resonance imaging in transthyretin amyloidosis patients treated with tafamidis

  • By

  • Franz Duca

  • Michael Poledniczek

  • Christina Kronberger

  • Christina Binder

  • René Rettl

  • Luciana Camuz-Ligios

  • Hermine Agis

  • Matthias Koschutnik

  • Carolina Donà

  • Roza Badr-Eslam

  • Dietrich Beitzke

  • Christian Loewe

  • Christian Nitsche

  • Christian Hengstenberg

  • Johannes Kastner

  • Jutta Bergler-Klein

  • Andreas Anselm Kammerlander

  • July 16, 2025

  • 0 min

Share

  • 1

    Cardiac transthyretin amyloidosis (ATTR CA) is a significant cause of heart failure with poor prognosis in advanced stages.

  • 2

    Cardiac magnetic resonance (CMR) T1-mapping is a validated, non-invasive method for quantifying extracellular volume (ECV) in ATTR CA.

  • 3

    Tafamidis treatment stabilizes ECV in ATTR CA patients, while treatment-naïve patients show an increase in ECV.

  • 4

    The study aims to investigate the prognostic relevance of serial ECV quantification in tafamidis-treated ATTR CA patients.

  • 5

    A decrease in amyloid burden assessed through CMR T1-mapping may predict better outcomes for ATTR CA patients treated with tafamidis.

Original Source(s)

Related Content